This new article publication from Acta Pharmaceutica Sinica B, discusses how an innovative and stable mRNA-LNP microneedle vaccine elicits humoral and multifunctional cellular immune responses.

Our NAV-005 antagonist binds the immunosuppressive HIO-1 factor and blocks its ability to suppress mAb, TCE and ADC ...

“We believe that vaccines that stimulate all three pillars of immunity – humoral, cellular and mucosal – have the potential to be powerful public health tools that prevent symptomatic infection as ...

A simple and widely deployable microneedle (MN) vaccine delivery system (mLNP-man-MN) was developed for mannose-modified LNPs (mLNP-man) loaded with mRNA encoding the SARS-CoV-2 spike receptor-binding ...